Relief Therapeutics Holding AG (RLF.SW)
CHF 4.1
(-6.82%)
CHF 4.1
(-6.82%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -110.82 Million CHF | 45.54% |
| 2022 | -36.54 Million CHF | -3.8% |
| 2021 | -35.21 Million CHF | -82.45% |
| 2020 | -19.29 Million CHF | -1937.8% |
| 2019 | -947 Thousand CHF | -89.4% |
| 2018 | -500 Thousand CHF | 59.84% |
| 2017 | -1.24 Million CHF | 92.45% |
| 2016 | -16.48 Million CHF | -331.75% |
| 2015 | -3.81 Million CHF | 68.45% |
| 2014 | -12.1 Million CHF | -5.5% |
| 2013 | -11.47 Million CHF | -85.66% |
| 2012 | -6.17 Million CHF | 89.56% |
| 2011 | -59.16 Million CHF | -207.39% |
| 2010 | -19.24 Million CHF | -58.97% |
| 2009 | -12.1 Million CHF | -32.05% |
| 2008 | -9.16 Million CHF | -428.68% |
| 2007 | -1.73 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.05 Million CHF | 0.0% |
| 2023 Q2 | -11.64 Million CHF | 0.0% |
| 2023 FY | -19.9 Million CHF | 45.54% |
| 2023 Q4 | -8.25 Million CHF | 0.0% |
| 2022 FY | -36.54 Million CHF | -3.8% |
| 2022 Q2 | -20.96 Million CHF | 0.0% |
| 2022 Q4 | -15.57 Million CHF | 0.0% |
| 2021 Q2 | -14.95 Million CHF | 0.0% |
| 2021 Q4 | -17.73 Million CHF | 0.0% |
| 2021 FY | -35.21 Million CHF | -82.45% |
| 2020 Q2 | -3.5 Million CHF | 0.0% |
| 2020 FY | -19.29 Million CHF | -1937.8% |
| 2020 Q4 | -15.79 Million CHF | 0.0% |
| 2019 Q2 | -421 Thousand CHF | 0.0% |
| 2019 FY | -947 Thousand CHF | -89.4% |
| 2019 Q4 | -526 Thousand CHF | 0.0% |
| 2018 Q2 | -422 Thousand CHF | 0.0% |
| 2018 Q4 | -78 Thousand CHF | 0.0% |
| 2018 FY | -500 Thousand CHF | 59.84% |
| 2017 FY | -1.24 Million CHF | 92.45% |
| 2017 Q4 | -686 Thousand CHF | 0.0% |
| 2017 Q2 | -1.05 Million CHF | 0.0% |
| 2016 Q1 | -4.2 Million CHF | 0.0% |
| 2016 FY | -16.48 Million CHF | -331.75% |
| 2016 Q2 | -271 Thousand CHF | 93.55% |
| 2016 Q4 | -1.66 Million CHF | 0.0% |
| 2015 Q3 | -2.28 Million CHF | 0.0% |
| 2015 FY | -3.81 Million CHF | 68.45% |
| 2015 Q1 | -2.28 Million CHF | 0.0% |
| 2015 Q4 | -4.2 Million CHF | -84.31% |
| 2015 Q2 | -2.28 Million CHF | 0.0% |
| 2014 Q4 | -2.28 Million CHF | 26.75% |
| 2014 FY | -12.1 Million CHF | -5.5% |
| 2014 Q3 | -3.11 Million CHF | 0.0% |
| 2014 Q2 | -3.11 Million CHF | 0.0% |
| 2014 Q1 | -3.11 Million CHF | 0.0% |
| 2013 Q4 | -3.11 Million CHF | -0.51% |
| 2013 Q3 | -3.09 Million CHF | 0.0% |
| 2013 Q2 | -3.09 Million CHF | 0.0% |
| 2013 Q1 | -3.09 Million CHF | 0.0% |
| 2013 FY | -11.47 Million CHF | -85.66% |
| 2012 FY | -6.17 Million CHF | 89.56% |
| 2012 Q4 | -3.09 Million CHF | -91.03% |
| 2012 Q2 | -1.62 Million CHF | 0.0% |
| 2012 Q1 | -1.62 Million CHF | 0.0% |
| 2012 Q3 | -1.62 Million CHF | 0.0% |
| 2011 Q2 | -14.7 Million CHF | 0.0% |
| 2011 Q4 | -1.62 Million CHF | 88.98% |
| 2011 FY | -59.16 Million CHF | -207.39% |
| 2011 Q3 | -14.7 Million CHF | 0.0% |
| 2011 Q1 | -14.7 Million CHF | 0.0% |
| 2010 Q1 | -4.74 Million CHF | 0.0% |
| 2010 Q4 | -14.7 Million CHF | -209.73% |
| 2010 Q3 | -4.74 Million CHF | 0.0% |
| 2010 Q2 | -4.74 Million CHF | 0.0% |
| 2010 FY | -19.24 Million CHF | -58.97% |
| 2009 Q2 | -2.97 Million CHF | 0.0% |
| 2009 Q3 | -2.97 Million CHF | 0.0% |
| 2009 Q4 | -4.74 Million CHF | -59.68% |
| 2009 FY | -12.1 Million CHF | -32.05% |
| 2009 Q1 | -2.97 Million CHF | 0.0% |
| 2008 Q4 | -2.97 Million CHF | -37.99% |
| 2008 Q2 | -2.15 Million CHF | 0.0% |
| 2008 Q1 | -2.15 Million CHF | 0.0% |
| 2008 FY | -9.16 Million CHF | -428.68% |
| 2008 Q3 | -2.15 Million CHF | 0.0% |
| 2007 FY | -1.73 Million CHF | 0.0% |
| 2007 Q3 | -277.72 Thousand CHF | 0.0% |
| 2007 Q2 | -277.72 Thousand CHF | 0.0% |
| 2007 Q1 | -277.72 Thousand CHF | 0.0% |
| 2007 Q4 | -2.15 Million CHF | -676.02% |
| 2006 Q4 | -277.72 Thousand CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.31 Million CHF | -974.833% |
| BB Biotech AG | -29.92 Million CHF | -270.315% |
| Basilea Pharmaceutica AG | 19.2 Million CHF | 677.079% |
| Evolva Holding SA | -92.24 Million CHF | -20.145% |
| Idorsia Ltd | -543.05 Million CHF | 79.592% |
| Kuros Biosciences AG | -13.19 Million CHF | -740.115% |
| Molecular Partners AG | -61.1 Million CHF | -81.364% |
| Santhera Pharmaceuticals Holding AG | 68.84 Million CHF | 260.984% |